Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Barbe F, Castan MT, Seminario MA, Pujol J, Alseda M. Prevalence and characteristics of chronic obstructive pulmonary disease in non-smokers. Aten Primaria. 2019 Dec;51(10):602-9. doi: 10.1016/j.aprim.2017.10.012
Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Barbe F, Castan MT, Seminario MA, Pujol J, Alseda M. Comment: Prevalence and characteristics of chronic obstructive pulmonary disease in non-smokers. Aten Primaria. 2019 Nov;51(9):589-90.
Blonde L, Raccah D, Lew E, Meyers J, Nikonova E, Ajmera M, Davis KL, Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin. Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, Martin AA. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017 Dec;8(6):1365-78. doi: 10.1007/s13300-017-0326-8
Cruz-Esteve I, Marsal-Mora JR, Galindo-Ortego G, Galvan-Santiago L, Serrano-Godoy M, Ribes-Murillo E, Real-Gatius J, en representacion del grupo de investigacion GRETAP. Potentially inappropriate prescribing in older Spanish population according to STOPP/START criteria (STARTREC Study). Aten Primaria. 2017 Mar;49(3):166-76. doi: 10.1016/j.aprim.2016.02.013
Montserrat-Capdevila J, Godoy P, Marsal JR, Barbe-Illa F. Risk factors for mortality in patients with chronic obstructive pulmonary disease. Aten Primaria. 2015 Oct;47(8):498-504. doi: 10.1016/j.aprim.2014.11.004
Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, Deeg MA. Physician preferences for extra-glycemic effects of type 2 diabetes treatments. Diabetes Ther. 2013 Dec;4(2):443-59. doi: 10.1007/s13300-013-0046-7.
Puente D, Zabaleta-Del-Olmo E, Pueyo MJ, Salto E, Marsal JR, Bolibar B. Cigarette smoking prevalence and associated factors in secondary school children in Catalunya. Aten Primaria. 2013 Jun;45(6):315-23. doi: 10.1016/j.aprim.2012.12.007
Mauskopf J, Chirila C, Birt J, Boye KS, Bowman L. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget? Health Policy (New York). 2013 Apr 1;110(1):49-59.
Dickey H, Ikenwilo D, Norwood P, Watson V, Zangelidis A. Utilisation of eye-care services: the effect of Scotland's free eye examination policy. Health Policy (New York). 2012 Dec;108(2-3):286-93. doi: 10.1016/j.healthpol.2012.09.006
Watson V, Sussex J, Ryan M, Tetteh E. Managing poorly performing clinicians: health care providers' willingness to pay for independent help. Health Policy (New York). 2012 Mar;104(3):260-71. doi: 10.1016/j.healthpol.2011.12.006
Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy (New York). 2008 Sep 1;87(3):342-9.
Lovas K, Kalo Z, McKenna SP, Whalley D, Pentek M, Genti G. Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. Health Policy (New York). 2003 Jan 1;63(1):20.
McKenna SP, Whalley D. Assessment of biotechnology drugs: what are the issues? Letter to the editor. Health Policy (New York). 1999 Nov;49(3):195-7. doi: 10.1016/S0168-8510(99)00055-X